These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9293964)

  • 1. Beneficial effects of bradykinin on myocardial energy metabolism and infarct size.
    Linz W; Wiemer G; Schölkens BA
    Am J Cardiol; 1997 Aug; 80(3A):118A-123A. PubMed ID: 9293964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.
    Linz W; Wiemer G; Schölkens BA
    Diabetes; 1996 Jan; 45 Suppl 1():S51-8. PubMed ID: 8529801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
    Linz W; Schölkens BA
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat.
    Wollert KC; Studer R; Doerfer K; Schieffer E; Holubarsch C; Just H; Drexler H
    Circulation; 1997 Apr; 95(7):1910-7. PubMed ID: 9107180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.
    Wolfrum S; Richardt G; Dominiak P; Katus HA; Dendorfer A
    Br J Pharmacol; 2001 Sep; 134(2):370-4. PubMed ID: 11564655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The kallikrein-kinin system in post-myocardial infarction cardiac remodeling.
    Wollert KC; Drexler H
    Am J Cardiol; 1997 Aug; 80(3A):158A-161A. PubMed ID: 9293971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia.
    Messadi E; Vincent MP; Griol-Charhbili V; Mandet C; Colucci J; Krege JH; Bruneval P; Bouby N; Smithies O; Alhenc-Gelas F; Richer C
    FASEB J; 2010 Dec; 24(12):4691-700. PubMed ID: 20667972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies].
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Z Kardiol; 1994; 83 Suppl 4():53-6. PubMed ID: 7856280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local inhibition of bradykinin degradation in ischemic hearts.
    Linz W; Martorana PA; Schölkens BA
    J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.
    Nolly H; Miatello R; Damiani MT; Abate CD
    Immunopharmacology; 1997 Jun; 36(2-3):185-91. PubMed ID: 9228545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
    Liu YH; Yang XP; Sharov VG; Nass O; Sabbah HN; Peterson E; Carretero OA
    J Clin Invest; 1997 Apr; 99(8):1926-35. PubMed ID: 9109437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulsatile antagonism on bradykinin 2-receptor (BK2R) by icatibant triggers the most effective kinin-dependent post-conditioning on rat hearts.
    Sgarra L; Coco C; Montagnani M; Potenza MA
    Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4439-4447. PubMed ID: 31173320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.
    Linz W; Wiemer G; Schölkens BA
    Braz J Med Biol Res; 1994 Aug; 27(8):1949-54. PubMed ID: 7749386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation.
    Miki T; Miura T; Ura N; Ogawa T; Suzuki K; Shimamoto K; Iimura O
    J Am Coll Cardiol; 1996 Nov; 28(6):1616-22. PubMed ID: 8917279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 2 bradykinin-receptor antagonism does not modify kinin or angiotensin peptide levels.
    Campbell DJ; Kladis A; Briscoe TA; Zhuo J
    Hypertension; 1999 May; 33(5):1233-6. PubMed ID: 10334817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
    Koid SS; Ziogas J; Campbell DJ
    Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion.
    Yin H; Chao L; Chao J
    Life Sci; 2008 Jan; 82(3-4):156-65. PubMed ID: 18068196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury.
    Wang LX; Ideishi M; Yahiro E; Urata H; Arakawa K; Saku K
    Hypertens Res; 2001 Mar; 24(2):179-87. PubMed ID: 11325078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes.
    Vora JP; Oyama TT; Thompson MM; Anderson S
    Diabetes; 1997 Jan; 46(1):107-12. PubMed ID: 8971089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.